Free Trial
NASDAQ:ALLR

Allarity Therapeutics (ALLR) Stock Price, News & Analysis

Allarity Therapeutics logo
$1.40
-0.06 (-4.11%)
(As of 10/31/2024 ET)

About Allarity Therapeutics Stock (NASDAQ:ALLR)

Key Stats

Today's Range
$1.34
$1.44
50-Day Range
$1.39
$5.49
52-Week Range
$1.26
$666.00
Volume
188,839 shs
Average Volume
256,020 shs
Market Capitalization
$1.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Allarity Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
17th Percentile Overall Score

ALLR MarketRank™: 

Allarity Therapeutics scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Percentage of Shares Shorted

    11.90% of the float of Allarity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Allarity Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Allarity Therapeutics has recently decreased by 21.10%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Allarity Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Allarity Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.90% of the float of Allarity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Allarity Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Allarity Therapeutics has recently decreased by 21.10%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Allarity Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Allarity Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for ALLR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Allarity Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.08% of the stock of Allarity Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 11.53% of the stock of Allarity Therapeutics is held by institutions.

  • Read more about Allarity Therapeutics' insider trading history.
Receive ALLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLR Stock News Headlines

War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update
See More Headlines

ALLR Stock Analysis - Frequently Asked Questions

Allarity Therapeutics' stock was trading at $330.66 at the beginning of 2024. Since then, ALLR shares have decreased by 99.6% and is now trading at $1.4041.
View the best growth stocks for 2024 here
.

Allarity Therapeutics, Inc. (NASDAQ:ALLR) issued its quarterly earnings results on Monday, August, 5th. The company reported ($3.30) EPS for the quarter.

Allarity Therapeutics's stock reverse split on the morning of Wednesday, September 11th 2024. The 1-30 reverse split was announced on Wednesday, September 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allarity Therapeutics investors own include AMC Entertainment (AMC), Plug Power (PLUG), Adial Pharmaceuticals (ADIL), Cara Therapeutics (CARA), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH) and Nuwellis (NUWE).

Company Calendar

Last Earnings
8/05/2024
Today
10/31/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALLR
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
$-11,900,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($559.31) per share

Miscellaneous

Free Float
1,410,000
Market Cap
$2.06 million
Optionable
Not Optionable
Beta
0.30
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:ALLR) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners